Rare liver itch pill eased itching and cut bile acids by 69%
In the phase 3 EXPAND trial, maralixibat cut worst daily itch by nearly a point versus placebo and reduced serum bile acids by 69% in ultra-rare cholestatic liver diseases.
12 October 2026
Clinical trials, drug development and research news
Tag
In the phase 3 EXPAND trial, maralixibat cut worst daily itch by nearly a point versus placebo and reduced serum bile acids by 69% in ultra-rare cholestatic liver diseases.
12 October 2026